When injured, the human skin is repaired through a wound-healing process that forms fibrotic scar tissue. Scarring burdens ...

Mitsubishi Tanabe Pharma Corp., Veneno Technologies Co. Ltd. and Alpha Fusion Co. Ltd. have initiated a joint research collaboration in Japan to develop cancer drugs using targeted alpha therapy (TAT) ...

Roche AG subsidiary Chugai Pharmaceutical Co. Ltd. and Singapore’s Gero Pte. Ltd. plan to tackle age-related diseases by collaborating to identify drug targets through Gero’s AI-driven human ...

Researchers from Nikang Therapeutics Inc. and Shanghai Blueray Biopharma Co. Ltd. have discovered GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.

Regulonix LLC and the U.S. Department of Health and Human Services (HHS) have jointly patented new sodium channel protein type 9 subunit α (SCN9A; Nav1.7) blockers reported to be useful for the ...

Hemolytic uremic syndrome (HUS) is a severe condition that primarily affects young children and typically occurs after a gastrointestinal infection with Shiga toxin 2 (Stx2)-producing Escherichia coli ...

Toll-like receptor 3 (TLR3) has been noted to impact liver disease and promote liver inflammation. Researchers from Southern Medical University screened a natural product molecular library and found ...

Prostate cancer is one of the most common male-related cancers, and understanding the underlying mechanisms is crucial for developing new treatment strategies and avoiding resistance development.

FAST kinase domain-containing protein 5 (FASTKD5) is a mitochondrial protein that is needed for processing mRNA in the primary mitochondrial transcript. Several mutations have been found in other ...

Dana Farber Cancer Institute Inc. and Stanford University have patented new molecular glue degraders comprising cereblon (CRBN) binding moiety acting as casein kinase 1 isoform α and/or wee1-like ...

Adipose tissue is essential for energy balance, but its dysfunction due to excessive lipid accumulation contributes to metabolic disorders such as insulin resistance, dyslipidemia and type 2 diabetes.

Eli Lilly & Co. has divulged relaxin receptor 1 (RXFP1; LGR7) agonists reported to be useful for the treatment of diabetes, stroke, atherosclerosis, pulmonary hypertension, chronic obstructive ...